Literature DB >> 2706726

The distribution and implications of BCG scars in northern Malawi.

P E Fine, J M Ponnighaus, N Maine.   

Abstract

Reported are data on the BCG scar status of more than 112,000 individuals who were surveyed in Karonga District, northern Malawi, between 1979 and 1984. The age and sex patterns of apparent BCG scars reflect the history of BCG vaccination activities in the district. Repeated independent examinations of large numbers of people revealed that the proportions remaining with the same observed scar status among those initially classified as being scar "positive" or scar "negative" were each approximately 90%. The repeatability of positive scar reading was lower among children and older adults than among young adults aged 15-24 years, and blind follow-up of children known to have been vaccinated as infants in child health clinics indicated that less than 60% had a detectable scar 3 years after receiving the vaccine. "Negative" repeatability increased consistently with age. The implications of these findings for estimating BCG vaccine uptake and for assessing its efficacy in case-control and cohort studies are discussed. The finding that BCG scars may be difficult to read suggests there is a danger of observer bias that could lead to distortion--in particular, to overestimates of vaccine efficacy.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Delivery Of Health Care; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Health; Health Services; Immunization; Infections; Malawi; Primary Health Care; Tuberculosis

Mesh:

Substances:

Year:  1989        PMID: 2706726      PMCID: PMC2491224     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Bias due to misclassification in the estimation of relative risk.

Authors:  K T Copeland; H Checkoway; A J McMichael; R H Holbrook
Journal:  Am J Epidemiol       Date:  1977-05       Impact factor: 4.897

Review 2.  BCG vaccination against tuberculosis and leprosy.

Authors:  P E Fine
Journal:  Br Med Bull       Date:  1988-07       Impact factor: 4.291

3.  The use of jet-injectors in BCG vaccination.

Authors:  H G ten Dam; C Fillastre; G Conge; E Orssaud; C Gateff; A Tanaka; O O Ramirez; J Wright; R Collas; L Chambon; M Barme; U B Tommasi; H Sarrat; P Bres; L Diallo; M Gauthier; M Piot; J Guld
Journal:  Bull World Health Organ       Date:  1970       Impact factor: 9.408

4.  Assay in man of different BCG products.

Authors:  J Nyboe; K Bunch-Christensen
Journal:  Bull World Health Organ       Date:  1966       Impact factor: 9.408

5.  Evaluating interventions against tropical diseases.

Authors:  P G Smith
Journal:  Int J Epidemiol       Date:  1987-06       Impact factor: 7.196

6.  Protective efficacy of BCG against leprosy in Northern Malawi.

Authors:  P E Fine; J M Ponnighaus; N Maine; J A Clarkson; L Bliss
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

  6 in total
  20 in total

1.  BCG revaccination and tuberculin reactivity.

Authors:  N Kuyucu; S Kuyucu; A Bakirtas; C Karacan
Journal:  Indian J Pediatr       Date:  2001-01       Impact factor: 1.967

2.  Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.

Authors:  Patricio Escalante; Kirstin J Kooda; Rizwana Khan; San San Aye; Stratos Christianakis; Daniel G Arkfeld; Glenn R Ehresmann; Jens J Kort; Brenda E Jones
Journal:  Lung       Date:  2014-10-16       Impact factor: 2.584

3.  Comparison of an in-house and a commercial RD1-based ELISPOT-IFN-gamma assay for the diagnosis of Mycobacterium tuberculosis infection.

Authors:  Paola Mantegani; Federica Piana; Luigi Codecasa; Laura Galli; Paolo Scarpellini; Adriano Lazzarin; Daniela Cirillo; Claudio Fortis
Journal:  Clin Med Res       Date:  2006-12

4.  Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996.

Authors:  J A Odhiambo; M W Borgdorff; F M Kiambih; D K Kibuga; D O Kwamanga; L Ng'ang'a; R Agwanda; N A Kalisvaart; O Misljenovic; N J Nagelkerke; M Bosman
Journal:  Am J Public Health       Date:  1999-07       Impact factor: 9.308

5.  Immunogenicity and safety of early vs delayed BCG vaccination in moderately preterm (31-33 weeks) infants.

Authors:  Megha Saroha; M M A Faridi; Prerna Batra; Iqbal Kaur; D K Dewan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Vitamin A levels and immunity in humans.

Authors:  Janine Jason; Lennox K Archibald; Okey C Nwanyanwu; Anne L Sowell; Ian Buchanan; Joshua Larned; Michael Bell; Peter N Kazembe; Hamish Dobbie; William R Jarvis
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

7.  Tuberculin response in BCG vaccinated schoolchildren and the estimation of annual risk of infection in Hong Kong.

Authors:  C C Leung; W W Yew; C M Tam; C K Chan; K C Chang; W S Law; S N Lee; M Y Wong; K F Au
Journal:  Thorax       Date:  2005-02       Impact factor: 9.139

8.  Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring.

Authors:  Janine Jason; Lennox K Archibald; Okey C Nwanyanwu; Peter N Kazembe; Julie A Chatt; Elizabeth Norton; Hamish Dobbie; William R Jarvis
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

9.  Association of interleukin-10 cytokine expression status with HLA non-DRB1*02 and Mycobacterium bovis BCG scar-negative status in south Indian pulmonary tuberculosis patients.

Authors:  V Dheenadhayalan; S Shanmugalakshmi; S Vani; P Muthuveeralakshmi; G Arivarignan; A D Nageswari; R M Pitchappan
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

10.  What has Karonga taught us? Tuberculosis studied over three decades.

Authors:  A C Crampin; J R Glynn; P E M Fine
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.